WHO Drug Information Vol. 25, No. 2, 2011

Proposed INN: List 105 WHO Drug Information Vol. 25, No. 2, 2011AMENDMENTS TO PREVIOUS LISTSMODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURESMODIFICACIONES A LAS LISTAS ANTERIORESProposed International Non Proprietary Names (Prop. INN): List 89Denominations communes internationales proposées (DCI Prop.): Liste 89Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 89(WHO Drug Information, Vol. 17, No. 3, 2003)p. 188 cantuzumabummertansinum #cantuzumab mertansinecantuzumab mertansinecantuzumab mertansinareplace the description, the mechanism of action and the structure by thefollowingremplacer la description, le mécanisme d'action et la structure par lessuivantssustitúyase el nombre químico, el mecanismo de acción y la estructura porlos siguientesimmunoglobulin G1-kappa, anti-[Homo sapiens MUC1 sialylatedcarbohydrate, tumour-associated (CA242, cancer antigen 242)], humanizedmonoclonal antibody conjugated to maytansinoid DM1;gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV7-4-1*02(76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfide with kappa lightchain (1’-219’) [humanized V-KAPPA (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer;conjugated, on an average of 4 lysyl, to maytansinoid DM1 [N 2’ -deacetyl-N 2’ -(3-mercapto-1-oxopropyl)-maytansine] via the reductible SPP linker[N-succinimidyl 4-(2-pyridyldithio)pentanoate]For the mertansine part, please refer to the document "INN for pharmaceuticalsubstances: Names for radicals, groups and others"*treatment of tumors that express CA242 antigenimmunoglobuline G1-kappa, anti-[Homo sapiens glycane sialylé de MUC1,associé à des tumeurs (CA242, antigène du cancer 242)], anticorpsmonoclonal humanisé conjugué au maytansinoïde DM1;chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens IGHV7-4-1*02(76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfure avec la chaînelégère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens IGKV2-28*01(82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au maytansinoïde DM1[N 2’ -déacétyl-N 2’ -(3-mercapto-1-oxopropyl)-maytansine] via le linker SPPréductible [4-(2-pyridyldithio)pentanoate de N-succinimidyle]Pour la partie mertansine, veuillez vous référer au document "INN forpharmaceutical substances: Names for radicals, groups and others"*.antitumoral spécifique des cellules exprimant l'antigène CA242200